This is a working overview of receptor agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-19 and is reviewed periodically as new material appears.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | 31 amino acids |
| Backbone modification | Aib at position 8 | Blocks DPP-4 cleavage |
| Fatty acid chain | C18 diacid | Supports albumin binding |
| Native half-life | 1 to 2 minutes | Endogenous GLP-1 |
| Analog half-life | Approximately one week | Extended by albumin binding |
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
In December 2013, a Formal Dispute Resolution was filed, which contained the requirements of the FDA for further studies. These include two studies in healthy subjects to determine if flibanserin impairs their ability to drive, and to determine if it interferes with other biochemical pathways. The Agency agreed to call a new Advisory Committee meeting to consider whether the risk-benefit ratio of flibanserin was favorable after this additional data was obtained. In June 2015, the US FDA Advisory Committee, which includes the Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSRM), recommended approval of the drug by 18–6, with the proviso that measures be taken to inform women of the drug's side effects. On 18 August 2015, the FDA approved Addyi (flibanserin) for the treatment of premenopausal women with low sexual desire that causes personal distress or relationship difficulties. The approval specified that flibanserin should not be used to treat low sexual desire caused by co-existing psychiatric or medical problems; low sexual desire caused by problems in the relationship; or low sexual desire due to medication side effects. As of August 2015, Sprout Pharmaceuticals had not yet made an application to the European Medicines Agency for a marketing authorization.
=== 1969 === January 20: Richard Nixon becomes President of the United States. March 2: Border clashes between the Soviet Union and China. March 17: the U.S. begins bombing Communist sanctuaries in Cambodia. July 16: Apollo 11 is launched. July 20: the U.S. accomplishes the first crewed Moon landing, Apollo 11. Crewed by Neil Armstrong, "Buzz" Aldrin, and Michael Collins. July 24: Apollo 11 returns to Earth. July 25: "Vietnamization" begins with U.S. troop withdrawals from Vietnam and the burden of combat being placed on the South Vietnamese. September 1: Muammar Gaddafi overthrows the Libyan monarchy and expels British and American personnel. Libya aligns itself with the Soviet Union. September 2: North Vietnamese leader Ho Chi Minh dies. October 21: Siad Barre overthrows the government of Somalia in a bloodless coup. He declares himself President of Somalia and reorganizes the country into a one-party communist state; the Somali Democratic Republic. November 17: The Strategic Arms Limitation Talks begin in Helsinki. November 27–December 6: the al-Wadiah War was fought between South Yemen and Saudi Arabia. December 12: A bomb planted by far-right extremists sets off in a bank in Milan, Italy, killing 17 people and injuring 88. This event (remembered as the Piazza Fontana bombing) is one of the bloodiest terrorist attacks Italy would receive during the years of lead.
A sperm donor will usually be required to enter into a contract with a sperm bank to supply his semen, typically for a period of six to 24 months depending on the number of pregnancies which the sperm bank intends to produce from the donor. The contract may also specify the place and hours for donation, a requirement to notify the sperm bank in the case the donor acquires a sexual infection, and a requirement not to have intercourse or to masturbate for a period of usually 2–3 days before making a donation. A sperm donor generally produces and collects sperm at a sperm bank or clinic by masturbation in a private room or cabin, known as a 'men's production room' (UK), 'donor cabin' (DK), or a masturbatorium (US). Many of these facilities contain pornography such as videos/DVD, magazines, and/or photographs which may assist the donor in becoming aroused in order to facilitate production of the ejaculate, also known as the "semen sample" but the increasing usage of porn in the U.S. has dulled many men to its effects. Often, using any lubricant, saliva, oil, or anything else to lubricate and stimulate the genitals is prohibited, as it can contaminate the semen sample and have negative impacts on the quality and health of sperm. In some circumstances, it may also be possible for semen from donors to be collected during sexual intercourse with the use of a collection condom which results in higher sperm counts.
=== EC 2.5.1: Transferring alkyl or aryl groups, other than methyl groups (only sub-subclass identified to date) === EC 2.5.1.1: dimethylallyltranstransferase EC 2.5.1.2: thiamine pyridinylase EC 2.5.1.3: thiamine-phosphate diphosphorylase EC 2.5.1.4: Now EC 4.4.1.42 adenosylmethionine cyclotransferase EC 2.5.1.5: galactose-6-sulfurylase EC 2.5.1.6: methionine adenosyltransferase EC 2.5.1.7: UDP-N-acetylglucosamine 1-carboxyvinyltransferase EC 2.5.1.8: transferred to EC 2.5.1.75, tRNA dimethylallyltransferase EC 2.5.1.9: riboflavin synthase EC 2.5.1.10: (2E,6E)-farnesyl diphosphate synthase EC 2.5.1.11: Now covered by EC 2.5.1.84 (all-trans-nonaprenyl-diphosphate synthase [geranyl-diphosphate specific]) and EC 2.5.1.85 (all-trans-nonaprenyl diphosphate synthase [geranylgeranyl-diphosphate specific]) EC 2.5.1.12: deleted, now included with EC 2.5.1.18 glutathione transferase EC 2.5.1.13: deleted, now included with EC 2.5.1.18 glutathione transferase EC 2.5.1.14: deleted, now included with EC 2.5.1.18 glutathione transferase EC 2.5.1.15: dihydropteroate synthase EC 2.5.1.16: spermidine synthase EC 2.5.1.17: cob(I)yrinic acid a,c-diamide adenosyltransferase EC 2.5.1.18: glutathione transferase EC 2.5.1.19: 3-phosphoshikimate 1-carboxyvinyltransferase EC 2.5.1.20: rubber cis-polyprenylcistransferase EC 2.5.1.21: squalene synthase EC 2.5.1.22: spermine synthase EC 2.5.1.23: sym-norspermidine synthase EC 2.5.1.24: discadenine synthase EC 2.5.1.25: tRNA-uridine aminocarboxypropyltransferase EC 2.5.1.26: alkylglycerone-phosphate synthase EC 2.5.1.27: adenylate dimethylallyltransferase EC 2.5.1.28: dimethylallylcistransferase EC 2.5.1.29: farnesyltranstransferase EC 2.5.1.30: trans-hexaprenyltranstransferase EC 2.5.1.31: ditrans,polycis-undecaprenyl-diphosphate synthase [(2E,6E)-farnesyl-diphosphate specific] EC 2.5.1.32: 15-cis-phytoene synthase EC 2.5.1.33: deleted, now covered by EC 2.5.1.82 hexaprenyl diphosphate synthase [geranylgeranyl-diphosphate specific] and EC 2.5.1.83 hexaprenyl diphosphate synthase [(2E,6E)-farnesyl-diphosphate specific] EC 2.5.1.34: tryptophan dimethylallyltransferase EC 2.5.1.35: aspulvinone dimethylallyltransferase EC 2.5.1.36: trihydroxypterocarpan dimethylallyltransferase EC 2.5.1.37: Now EC 4.4.1.20, leukotriene-C4 synthase EC 2.5.1.38: isonocardicin synthase EC 2.5.1.39: 4-hydroxybenzoate polyprenyltransferase EC 2.5.1.40: Now EC 4.2.3.9, aristolochene synthase EC 2.5.1.41: phosphoglycerol geranylgeranyltransferase EC 2.5.1.42: geranylgeranylglycerol-phosphate geranylgeranyltransferase EC 2.5.1.43: nicotianamine synthase EC 2.5.1.44: homospermidine synthase EC 2.5.1.45: homospermidine synthase (spermidine-specific) EC 2.5.1.46: deoxyhypusine synthase EC 2.5.1.47: cysteine synthase EC 2.5.1.48: cystathionine γ-synthase EC 2.5.1.49: O-acetylhomoserine aminocarboxypropyltransferase EC 2.5.1.50: zeatin 9-aminocarboxyethyltransferase EC 2.5.1.51: β-pyrazolylalanine synthase EC 2.5.1.52: L-mimosine synthase EC 2.5.1.53: uracilylalanine synthase EC 2.5.1.54: 3-deoxy-7-phosphoheptulonate synthase EC 2.5.1.55: 3-deoxy-8-phosphooctulonate synthase EC 2.5.1.56: N-acetylneuraminate synthase EC 2.5.1.57: N-acylneuraminate-9-phosphate synthase EC 2.5.1.58: protein farnesyltransferase EC 2.5.1.59: protein geranylgeranyltransferase type I EC 2.5.1.60: protein geranylgeranyltransferase type II EC 2.5.1.61: hydroxymethylbilane synthase EC 2.5.1.62: chlorophyll synthase EC 2.5.1.63: adenosyl-fluoride synthase EC 2.5.1.64: The reaction that was attributed to this enzyme is now known to be catalysed by two separate enzymes: EC 2.2.1.9 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylic-acid synthase and EC 4.2.99.20 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate synthase EC 2.5.1.65: O-phosphoserine sulfhydrylase EC 2.5.1.66: N2-(2-carboxyethyl)arginine synthase EC 2.5.1.67: chrysanthemyl diphosphate synthase EC 2.5.1.68: (2Z,6E)-farnesyl diphosphate synthase EC 2.5.1.69: lavandulyl diphosphate synthase EC 2.5.1.70: naringenin 8-dimethylallyltransferase EC 2.5.1.71: leachianone-G 2′′-dimethylallyltransferase EC 2.5.1.72: quinolinate synthase EC 2.5.1.73: O-phospho-L-seryl-tRNA:Cys-tRNA synthase EC 2.5.1.74: 1,4-dihydroxy-2-naphthoate polyprenyltransferase EC 2.5.1.75: tRNA dimethylallyltransferase EC 2.5.1.76: cysteate synthase EC 2.5.1.77: Now EC 2.5.1.147, 5-amino-6-(D-ribitylamino)uracil—L-tyrosine 4-methylphenol transferase and EC 4.3.1.32, 7,8-didemethyl-8-hydroxy-5-deazariboflavin synthase. EC 2.5.1.78: 6,7-dimethyl-8-ribityllumazine synthase EC 2.5.1.79: thermospermine synthase EC 2.5.1.80: 7-dimethylallyltryptophan synthase EC 2.5.1.81: geranylfarnesyl diphosphate synthase EC 2.5.1.82: hexaprenyl diphosphate synthase [geranylgeranyl-diphosphate specific] EC 2.5.1.83: hexaprenyl diphosphate synthase [(2E,6E)-farnesyl-diphosphate specific] EC 2.5.1.84: all-trans-nonaprenyl-diphosphate synthase (geranyl-diphosphate specific) EC 2.5.1.85: all-trans-nonaprenyl diphosphate synthase [geranylgeranyl-diphosphate specific] EC 2.5.1.86: trans,polycis-decaprenyl diphosphate synthase EC 2.5.1.87: ditrans,polycis-polyprenyl diphosphate synthase [(2E,6E)-farnesyl diphosphate specific] EC 2.5.1.88: trans,polycis-polyprenyl diphosphate synthase [(2Z,6E)-farnesyl diphosphate specific] EC 2.5.1.89: tritrans,polycis-undecaprenyl diphosphate synthase [geranylgeranyl-diphosphate specific] EC 2.5.1.90: all-trans-octaprenyl-diphosphate synthase EC 2.5.1.91: all-trans-decaprenyl-diphosphate synthase EC 2.5.1.92: (2Z,6Z)-farnesyl diphosphate synthase EC 2.5.1.93: 4-hydroxybenzoate geranyltransferase EC 2.5.1.94: adenosyl-chloride synthase EC 2.5.1.95: xanthan ketal pyruvate transferase EC 2.5.1.96: 4,4′-diapophytoene synthase EC 2.5.1.97: pseudaminic acid synthase EC 2.5.1.98: Rhizobium leguminosarum exopolysaccharide glucosyl ketal-pyruvate-transferase EC 2.5.1.99: The activity was an artifact caused by photoisomerization of the product of EC 2.5.1.32, 15-cis-phytoene synthase EC 2.5.1.100: fumigaclavine A dimethylallyltransferase EC 2.5.1.101: N,N′-diacetyllegionaminate synthase EC 2.5.1.102: geranyl-pyrophosphate—olivetolic acid geranyltransferase EC 2.5.1.103: presqualene diphosphate synthase EC 2.5.1.104: N1-aminopropylagmatine synthase EC 2.5.1.105: 7,8-dihydropterin-6-yl-methyl-4-(β-D-ribofuranosyl)aminobenzene 5′-phosphate synthase EC 2.5.1.106: tryprostatin B synthase EC 2.5.1.107: verruculogen prenyltransferase EC 2.5.1.108: 2-(3-amino-3-carboxypropyl)histidine synthase EC 2.5.1.109: brevianamide F prenyltransferase (deoxybrevianamide E-forming) EC 2.5.1.110: 12α,13α-dihydroxyfumitremorgin C prenyltransferase EC 2.5.1.111: 4-hydroxyphenylpyruvate 3-dimethylallyltransferase EC 2.5.1.112: adenylate dimethylallyltransferase (ADP/ATP-dependent) EC 2.5.1.113: [CysO sulfur-carrier protein]-thiocarboxylate-dependent cysteine synthase EC 2.5.1.114: tRNAPhe (4-demethylwyosine37-C7) aminocarboxypropyltransferase EC 2.5.1.115: homogentisate phytyltransferase EC 2.5.1.116: homogentisate geranylgeranyltransferase EC 2.5.1.117: homogentisate solanesyltransferase EC 2.5.1.118: β-(isoxazolin-5-on-2-yl)-L-alanine synthase EC 2.5.1.119: β-(isoxazolin-5-on-4-yl)-L-alanine synthase EC 2.5.1.120: aminodeoxyfutalosine synthase EC 2.5.1.121: 5,10-dihydrophenazine-1-carboxylate 9-dimethylallyltransferase EC 2.5.1.122: 4-O-dimethylallyl-L-tyrosine synthase EC 2.5.1.123: flaviolin linalyltransferase EC 2.5.1.124: 6-linalyl-2-O,3-dimethylflaviolin synthase EC 2.5.1.125: 7-geranyloxy-5-hydroxy-2-methoxy-3-methylnaphthalene-1,4-dione synthase EC 2.5.1.126: norspermine synthase EC 2.5.1.127: caldopentamine synthase EC 2.5.1.128: N4-bis(aminopropyl)spermidine synthase EC 2.5.1.129: flavin prenyltransferase EC 2.5.1.130: 2-carboxy-1,4-naphthoquinone phytyltransferase EC 2.5.1.131: (4-{4-[2-(γ-L-glutamylamino)ethyl]phenoxymethyl}furan-2-yl)methanamine synthase EC 2.5.1.132: 3-deoxy-D-glycero-D-galacto-nonulopyranosonate 9-phosphate synthase EC 2.5.1.133: bacteriochlorophyll a synthase EC 2.5.1.134: cystathionine β-synthase (O-acetyl-L-serine) EC 2.5.1.135: validamine 7-phosphate valienyltransferase EC 2.5.1.136: 2-acylphloroglucinol 4-prenyltransferase EC 2.5.1.137: 2-acyl-4-prenylphloroglucinol 6-prenyltransferase EC 2.5.1.138: coumarin 8-geranyltransferase EC 2.5.1.139: umbelliferone 6-dimethylallyltransferase EC 2.5.1.140: N-(2-amino-2-carboxyethyl)-L-glutamate synthase EC 2.5.1.141: heme o synthase EC 2.5.1.142: nerylneryl diphosphate synthase EC 2.5.1.143: pyridinium-3,5-biscarboxylic acid mononucleotide synthase EC 2.5.1.144: S-sulfo-L-cysteine synthase (O-acetyl-L-serine-dependent) EC 2.5.1.145: phosphatidylglycerol—prolipoprotein diacylglyceryl transferase EC 2.5.1.146: 3-geranyl-3-[(Z)-2-isocyanoethenyl]indole synthase EC 2.5.1.147: 5-amino-6-(D-ribitylamino)uracil—L-tyrosine 4-hydroxyphenyl transferase EC 2.5.1.148: lycopaoctaene synthase EC 2.5.1.149: lycopene elongase/hydratase (flavuxanthin-forming) EC 2.5.1.150: lycopene elongase/hydratase (dihydrobisanhydrobacterioruberin-forming) EC 2.5.1.151: alkylcobalamin dealkylase EC 2.5.1.152: D-histidine 2-aminobutanoyltransferase EC 2.5.1.153: adenosine tuberculosinyltransferase
Nuclear magnetic resonance spectroscopy of proteins (usually abbreviated protein NMR) is a field of structural biology in which NMR spectroscopy is used to obtain information about the structure and dynamics of proteins, and also nucleic acids, and their complexes. The field was pioneered by Richard R. Ernst and Kurt Wüthrich at the ETH, and by Ad Bax, Marius Clore, Angela Gronenborn at the NIH, and Gerhard Wagner at Harvard University, among others. Structure determination by NMR spectroscopy usually consists of several phases, each using a separate set of highly specialized techniques. The sample is prepared, measurements are made, interpretive approaches are applied, and a structure is calculated and validated. NMR involves the quantum-mechanical properties of the central core ("nucleus") of the atom. These properties depend on the local molecular environment, and their measurement provides a map of how the atoms are linked chemically, how close they are in space, and how rapidly they move with respect to each other. These properties are fundamentally the same as those used in the more familiar magnetic resonance imaging (MRI), but the molecular applications use a somewhat different approach, appropriate to the change of scale from millimeters (of interest to radiologists) to nanometers (bonded atoms are typically a fraction of a nanometer apart), a factor of a million. This change of scale requires much higher sensitivity of detection and stability for long term measurement.
Sources: en.wikipedia.org
LEDs are made in different packages for different applications. A single or a few LED junctions may be packed in one miniature device for use as an indicator or pilot lamp. An LED array may include controlling circuits within the same package, which may range from a simple resistor, blinking or color changing control, or an addressable controller for RGB devices. Higher-powered white-emitting devices will be mounted on heat sinks and will be used for illumination. Alphanumeric displays in dot matrix or bar formats are widely available. Special packages permit connection of LEDs to optical fibers for high-speed data communication links.
==== Member of the Royal Victorian Order (MVO) ==== Russell Adams, , Custodian of California Stores, Royal Collection, Royal Household. Captain Andrew Mark Aspden, Royal Navy, lately Principal Private Secretary to The Duke and Duchess of Edinburgh. Ian Charles Bartlett, Clerk of the Works, Westminster Abbey, on the occasion of the Coronation of Their Majesties The King and The Queen. Nicholas John Birch, Sergeant, Metropolitan Police Service. For services to Royalty and Specialist Protection. Ian Leslie Bullock, , Security Officer Team Leader, Palace of Holyroodhouse. Emma Jane Clarke, Secretary, Royal Farms, Windsor. Nicola Charlotte Craig, Royal Borough of Windsor and Maidenhead, on the occasion of the Coronation Concert. Andrew John Cranidge, Superintendent, Thames Valley Police, on the occasion of the Coronation Concert. Anne Maria Curran, Personal and Administration Assistant, Superintendent's Office, Windsor Castle. Sarah Louise Davis, Head of Press and Marketing, Royal Collection, Royal Household. Julie Elizabeth Denby, lately Deputy Clerk/Administrator, Greater Manchester Lieutenancy. Michael Robert Duncan, lately Special Project Advisor, Royal Household, on the occasion of the Coronation of Their Majesties The King and The Queen. Hannah Elizabeth Evans, Programme Manager, Household of The Princess Royal. David Irwin Foy, Stud Groom, Royal Paddocks, Hampton Court Palace. Christopher William Andrew Hallworth, Senior Business Applications and Infrastructure Manager, Royal Collection, Royal Household.
=== Structural Biology and Protein Engineering === This program studies biomolecules using protein engineering and molecular biology techniques. Methodologies include X-ray crystallography and cryo-EM. Research includes protein structure determination and mass spectrometry methods.
Similar effects are known for related androgenic progestins like medroxyprogesterone acetate and megestrol acetate. CPA has also been reported to lower HDL cholesterol levels, another effect associated with androgens. Accordingly, CPA shows weak androgenic effects in the liver in rodents which can be blocked by flutamide.
Sources: en.wikipedia.org
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.
A fatty acid side chain attaches the peptide to serum albumin, which shields it from kidney filtration and protease activity. This interaction is the main reason its circulation time is extended.
No. The native hormone is GLP-1, and semaglutide is an engineered variant with three deliberate structural alterations. It does not appear in unmodified biological sources.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.